Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Consensus Rating of “Hold” by Brokerages

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been given a consensus recommendation of “Hold” by the five brokerages that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $3.33.

Separately, Wall Street Zen started coverage on shares of Syros Pharmaceuticals in a research note on Friday, May 16th. They issued a “sell” rating on the stock.

Syros Pharmaceuticals Trading Down 1.8%

NASDAQ:SYRS opened at $0.03 on Thursday. The stock has a market cap of $719,097.60, a P/E ratio of -0.01 and a beta of 1.31. The stock’s 50-day moving average is $0.03 and its 200-day moving average is $0.11. Syros Pharmaceuticals has a 1-year low of $0.02 and a 1-year high of $6.93.

Institutional Trading of Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC purchased a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned approximately 0.40% of Syros Pharmaceuticals as of its most recent filing with the SEC. 91.47% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.